Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Phase 1 Recruiting 90 enrolled Darell Bigner Rockefeller University · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 1 study of an anti-CD40 monoclonal antibody (2141-V11) in combination with D2C7-IT for patients with recurrent World Health Organization (WHO) grade III or IV malignant glioma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.

Timeline

Start: 2021-07-09
Primary completion: 2027-06
Completion: 2028-06

Publications

Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE 2nd, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, Knorr DA, Pastan IH, Nair SK, Bigner DD, Chandramohan V. Immunotoxin-alphaCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Sci Transl Med. 2023 Feb 8;15(682):eabn5649. doi: 10.1126/scitranslmed.abn5649. Epub 2023 Feb 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	2141-V11	Monoclonal antibody	2 mg	Other
Subject	D2C7-IT	Protein / enzyme biologic	4613.2 ng/ml	Other

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Summary

Timeline

Publications

Drugs

Indications